NCT06384248View on ClinicalTrials.gov

Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 26, 2024

Primary Completion Date

December 28, 2025

Study Completion Date

December 28, 2025

Conditions
Unresectable or Metastatic Sarcoma
Interventions
DRUG

LTC004

LTC004,45μg/kg,IV,Day 1,Q3W;

All Listed Sponsors
lead

Letolab

INDUSTRY

NCT06384248 - Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma | Biotech Hunter | Biotech Hunter